Moderna soars into the ranks of the world's top pharma players, now worth 3 Regenerons

As we got started this morning, there was quite a bit of interest in seeing if Moderna could break the $200 billion mark today on its market cap. The mRNA power player has seen its already steep stock price more than double in the past month — breaking the $100 billion ceiling a few weeks ago caused a few gasps — and the last few days has seen a sharp spike as the biotech laid out bullish prospects for its booster shot after nabbing a megabillion-dollar reward for its Covid-19 vaccine.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE

TRENDING NOW

Moderna soars into the ranks of the world's top pharma players, now worth 3 Regenerons

This article is for premium subscribers only

Patient dies in Pfizer’s Phase 2 Duchenne muscular dystrophy trial

After eight years with Sanofi, Frank Nestle departs as CSO, global head of research

'Bigger, faster, better': Isomorphic, DeepMind unveil AlphaFold 3, going beyond protein predictions

After CRISPR baby scandal shut down work for years, China gene editing companies are restarting clinical trials

Marinus lays off 20% of workforce, cuts costs to stay afloat

Medical Affairs: The Critical Link Between Science, Physicians and Patients

Mod­er­na soars in­to the ranks of the world's top phar­ma play­ers, now worth 3 Re­gen­erons

This article is for premium subscribers only

Pa­tient dies in Pfiz­er’s Phase 2 Duchenne mus­cu­lar dy­s­tro­phy tri­al

Af­ter eight years with Sanofi, Frank Nes­tle de­parts as CSO, glob­al head of re­search

'Big­ger, faster, bet­ter': Iso­mor­phic, Deep­Mind un­veil Al­phaFold 3, go­ing be­yond pro­tein pre­dic­tions

Af­ter CRISPR ba­by scan­dal shut down work for years, Chi­na gene edit­ing com­pa­nies are restart­ing clin­i­cal tri­als

Mar­i­nus lays off 20% of work­force, cuts costs to stay afloat

Med­ical Af­fairs: The Crit­i­cal Link Be­tween Sci­ence, Physi­cians and Pa­tients

Moderna soars into the ranks of the world's top pharma players, now worth 3 Regenerons

Patient dies in Pfizer’s Phase 2 Duchenne muscular dystrophy trial

After eight years with Sanofi, Frank Nestle departs as CSO, global head of research

'Bigger, faster, better': Isomorphic, DeepMind unveil AlphaFold 3, going beyond protein predictions

After CRISPR baby scandal shut down work for years, China gene editing companies are restarting clinical trials

Marinus lays off 20% of workforce, cuts costs to stay afloat

Medical Affairs: The Critical Link Between Science, Physicians and Patients